The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry. Between this year and 2016, $131 billion worth of drugs will come off patent, followed by a long decline often called the patent cliff. Facing this precipice, generic drug companies will have to adapt as the market becomes increasingly commoditized. Click below to download the PDF of the Generic Drugs Special Report.
The DSN PoweRx list represents nearly 80% of the total retail pharmacy business — including more than $250 billion in pharmacy sales and nearly 59,000 pharmacies. And with the rise of more consumer-centered health care, they are creating innovative programs and entering healthcare partnerships to move beyond dispensing and expand their role in the U.S. healthcare delivery system. Read more
Industry leaders talk soulful brands, doing good and operating with purpose at the third annual New General Market Summit. In this special report, DSN highlights the big ideas and best practices that emerged from the event.